

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Andrew R. Marks et al. Confirmation No.: 7653  
Application No.: 10/809,089 Art Unit: 1612  
Filed: March 25, 2004 Examiner: B. J. Packard  
Title: NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT  
TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2)  
AND USES THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Enclosed is the following item for filing in connection with the above-referenced Patent Application:

1. Supplemental Application Data Sheet (ADS)

This supplemental ADS is submitted to cancel certain claims to priority for the above-referenced application, and is in accordance with the Amendment to the Specification filed on May 21, 2008. As indicated in the supplemental ADS and in the prior filed Amendment to the Specification, Applicants wish to retain their claim to priority to U.S. Patent Application Serial No. 10/763,498, filed on January 22, 2004, now abandoned.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application

by this firm) to our Deposit Account No. 08-0219, under Order No. 0019240.00596US1. A duplicate copy of this paper is enclosed.

Respectfully submitted,

Dated: February 1, 2010

      /Jane M. Love, Ph.D./        
Jane M. Love, Ph.D.  
Registration No.: 42,812  
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
399 Park Avenue  
New York, New York 10022  
(212) 230-8800 (telephone)  
(212) 230-8888 (facsimile)